CM
AKRO

Caption Management’s Akero Therapeutics AKRO Stock Holding History

Caption Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-130,000
Closed -$6.17M – 1539
2025
Q3 		$6.17M Sell
130,000
-99,700
-43% -$4.83M 0.05% 415
2025
Q2 		$12.3M Buy
229,700
+188,700
+460% +$8.57M 0.14% 164
2025
Q1 		$1.66M Buy
+41,000
New +$1.74M 0.02% 749
2024
Q4 		– Sell
-42,500
Closed -$1.22M – 1435
2024
Q3 		$1.22M Buy
+42,500
New +$1.11M 0.02% 714
2024
Q2 		– Sell
-296,500
Closed -$7.49M – 1124
2024
Q1 		$7.49M Buy
+296,500
New +$7.12M 0.11% 224
2023
Q4 		– Sell
-143,000
Closed -$7.23M – 1313
2023
Q3 		$7.23M Buy
143,000
+113,000
+377% +$5.26M 0.11% 230
2023
Q2 		$1.4M Sell
30,000
-30,000
-50% -$1.37M 0.02% 590
2023
Q1 		$2.3M Buy
60,000
+30,000
+100% +$1.34M 0.04% 409
2022
Q4 		$1.64M Sell
30,000
-195,800
-87% -$8.39M 0.03% 610
2022
Q3 		$7.69M Buy
+225,800
New +$3.45M 0.11% 226

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Caption Management's AKRO Position: Q4 2025 in Review

Caption Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 39,500 shares — an estimated $1.88M sold.

Caption Management first reported a position in AKRO in Q1 2020 and held it in 11 quarters. The position peaked at $1.88M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Caption Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 39,500 Akero Therapeutics shares in Q4 2025, an estimated $1.88M.
  • Caption Management first reported a position in Akero Therapeutics in Q1 2020 and held it in 11 quarters.
  • Caption Management's Akero Therapeutics position peaked at $1.88M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.